Advanced Search

Journal of Traditional Chinese Medicine >

2025 , Vol. 45 >Issue 1: 39 - 48

DOI: https://doi.org/10.19852/j.cnki.jtcm.2025.01.004

Protective effect of lappaconitine on Freund's complete adjuvant-induced arthritis exerted through P2X7 receptor-mediated regulation of M1/M2 balance in rats

  • Pengqiang ZHANG ,
  • Qi FENG ,
  • Weiyan HUANG ,
  • Shan OU
Expand
  • 1 School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China
    2 Department of Anesthesiology, Chengdu First People's Hospital, Chengdu 610095, China

Received date: 2023-11-11

  Accepted date: 2024-04-15

  Online published: 2025-01-10

Fold

Abstract

OBJECTIVE: to investigate the anti-arthritic effects of lappaconitine (LA) on adjuvant-induced arthritis in Sprague-Dawley rats and its possible involvement in the regulation of M1/M2 macrophage balance through the P2X7 receptor (P2X7r).

METHODS: Rats were immunized with complete Freund’s adjuvant and then intraperitoneally administered LA (2, 4, or 8 mg·kg-1·d-1) or methotrexate (0.5 mg/kg per 3 d) for 14 d. The anti-arthritic effects of LA were evaluated through arthritis index (AI) assessment, ankle diameter measurement, and histopathological staining analysis. The analgesic effect of LA on arthritis was measured using mechanical withdrawal threshold testing and gait scoring. The impacts of LA on macrophage polarization, the expression of pro-/anti-inflammatory cytokines and P2X7r were analyzed using quantitative real-time polymerase chain reaction, enzyme-linked immunosorbent assay, and Western blotting.

RESULTS: LA treatment significantly reduced AI scores, paw swelling, joint destruction, and inflammatory cell infiltration, and alleviated arthritis pain. Additionally, LA promoted a balanced M1/M2 ratio by increasing the mRNA expression level of M2 marker arginase 1 and decreasing those of M1 markers inducible nitric oxide synthase and interleukin (IL)-1β in synovial tissues. Furthermore, LA lowered the levels of three M1-related cytokines, namely tumor necrosis factor-α, IL-1β and IL-18, and raised the level of the M2-related cytokine IL-10. Further research showed that treatment with LA inhibited the expression of P2X7r.

CONCLUSION: Our findings indicate that the notable therapeutic and analgesic effects of LA on AIA rats are exerted through balancing the M1/M2 ratio, probably via P2X7r.

Key words： arthritis, experimental; macrophage polarization; receptors, purinergic P2X7; anti-inflammatory agents; analgesics; lappaconitine

Cite this article

Pengqiang ZHANG , Qi FENG , Weiyan HUANG , Shan OU . Protective effect of lappaconitine on Freund's complete adjuvant-induced arthritis exerted through P2X7 receptor-mediated regulation of M1/M2 balance in rats[J]. Journal of Traditional Chinese Medicine, 2025 , 45(1) : 39 -48 . DOI: 10.19852/j.cnki.jtcm.2025.01.004

References

1. Finckh A, Gilbert B, Hodkinson B, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol 2022; 18: 591-602.
2. Christenson K, Bj?rkman L, T?ngemo C, Bylund J. Serum amyloid A inhibits apoptosis of human neutrophils via a P2X7-sensitive pathway independent of formyl peptide receptor-like 1. J Leukoc Biol 2008; 83: 139-48.
3. Dudics S, Langan D, Meka RR, et al. Natural products for the treatment of autoimmune arthritis: their mechanisms of action, targeted delivery, and interplay with the host microbiome. Int J Mol Sci 2018; 19: 2508.
4. Radner H, Yoshida K, Mjaavatten MD, et al. Development of a multimorbidity index: impact on quality of life using a rheumatoid arthritis cohort. Semin Arthritis Rheum 2015; 45: 167-73.
5. Krane SM, Simon LS. Rheumatoid arthritis: clinical features and pathogenetic mechanisms. Med Clin North Am 1986; 70: 263-84.
6. Akhtari M, Jalal Zargar S, Javinani A, et al. Prototypic P2X7 receptor agonist, BzATP, induced the expression of unfolded protein response genes in human M1 macrophages. Iran J Allergy Asthma Immunol 2022; 21: 73-80.
7. Gui X, Wang H, Wu L, et al. Botulinum toxin type A promotes microglial M2 polarization and suppresses chronic constriction injury-induced neuropathic pain through the P2X7 receptor. Cell Biosci 2020; 10: 45.
8. Nieto FR, Clark AK, Grist J, Hathway GJ, Chapman V, Malcangio M. Neuron-immune mechanisms contribute to pain in early stages of arthritis. J Neuroinflammation 2016; 13: 96.
9. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 2018; 6: 15.
10. Tang Y, Xie D, Gong W, Wu H, Qiang Y. Pentahydroxy flavonoid isolated from madhuca indica ameliorated adjuvant-induced arthritis via modulation of inflammatory pathways. Sci Rep 2021; 11: 17971.
11. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 79: 685-99.
12. Tong L, Nanjundaiah SM, Venkatesha SH, Astry B, Yu H, Moudgil KD. Pristimerin, a naturally occurring triterpenoid, protects against autoimmune arthritis by modulating the cellular and soluble immune mediators of inflammation and tissue damage. Clin Immunol 2014; 155: 220-30.
13. Venkatesha SH, Berman BM, Moudgil KD. Herbal medicinal products target defined biochemical and molecular mediators of inflammatory autoimmune arthritis. Bioorg Med Chem 2011; 19: 21-9.
14. Pang L, Liu CY, Gong GH, Quan ZS. Synthesis, in vitro and in vivo biological evaluation of novel lappaconitine derivatives as potential anti-inflammatory agents. Acta Pharm Sin B 2020; 10: 628-45.
15. Singhuber J, Zhu M, Prinz S, Kopp B. Aconitum in Traditional Chinese Medicine: a valuable drug or an unpredictable risk? J Ethnopharmacol 2009; 126: 18-30.
16. Gutser UT, Friese J, Heubach JF, et al. Mode of antinociceptive and toxic action of alkaloids of aconitum spec. Naunyn Schmiedebergs Arch Pharmacol 1998; 357: 39-48.
17. Tang M, Zhao W, Xing M, et al. Resource allocation strategies among vegetative growth, sexual reproduction, asexual reproduction and defense during growing season of aconitum kusnezoffii Reichb. Plant J 2021; 105: 957-77.
18. Shaheen F, Ahmad M, Khan MT, et al. Alkaloids of aconitum laeve and their anti-inflammatory antioxidant and tyrosinase inhibition activities. Phytochemistry 2005; 66: 935-40.
19. Yu JZ, Zhang BJ, Jiang XT. Clinical application of lappaconitine hydrobromide. Di Er Jun Yi Da Xue Xue Bao 2005; 26: 822-4.
20. Ameri A. The effects of aconitum alkaloids on the central nervous system. Prog Neurobiol 1998; 56: 211-35.
21. Zeng W, Shen C, Mo S, et al. The effective treatment of purpurin on inflammation and adjuvant-induced arthritis. Molecules 2023; 28: 366.
22. Arab HH, Salama SA, Abdelghany TM, et al. Camel milk attenuates rheumatoid arthritis via inhibition of mitogen activated protein kinase pathway. Cell Physiol Biochem 2017; 43: 540-52.
23. Ou S, Zhao YD, Xiao Z, Wen HZ, Cui J, Ruan HZ. Effect of lappaconitine on neuropathic pain mediated by P2X3 receptor in rat dorsal root ganglion. Neurochem Int 2011; 58: 564-73.
24. Chen F, Shen X, Huang P, Fu H, Jin Y, Wen C. Quantification of lappaconitine in mouse blood by UPLC-MS/MS and its application to a pharmacokinetic study. Biomed Res Int 2019; 6: 6262105.
25. Lei B, Wang SH, Wang ZM. Lappaconitine inhibits inflammatory pain by inhibiting microglial activation. Yanan Da Xue Xue Bao 2019; 17: 7-10 + 22.
26. Abdel-Maged AE, Gad AM, Wahdan SA, Azab SS. Efficacy and safety of ramucirumab and methotrexate co-therapy in rheumatoid arthritis experimental model: involvement of angiogenic and immunomodulatory signaling. Toxicol Appl Pharmacol 2019; 380: 114702.
27. Abdel Jaleel GA, Azab SS, El-Bakly WM, Hassan A. 'Methyl palmitate attenuates adjuvant induced arthritis in rats by decrease of CD68 synovial macrophages. Biomed Pharmacother 2021; 137: 111347.
28. Mathias K, Amarnani A, Pal N, et al. Chronic pain in patients with rheumatoid arthritis. Curr Pain Headache Rep 2021; 25: 59.
29. Walsh DA, McWilliams DF. Mechanisms, impact and management of pain in rheumatoid arthritis. Nat Rev Rheumatol 2014; 10: 581-92.
30. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-69.
31. Abeles AM, Pillinger MH. The role of the synovial fibroblast in rheumatoid arthritis: cartilage destruction and the regulation of matrix metalloproteinases. Bull NYU Hosp Jt Dis 2006; 64: 20-4.
32. Yu Y, Cai W, Zhou J, et al. Anti-arthritis effect of berberine associated with regulating energy metabolism of macrophages through AMPK/ HIF-1α pathway. Int Immunopharmacol 2020; 87: 106830.
33. Ma Y, Di R, Zhao H, Song R, Zou H, Liu Z. P2X7 receptor knockdown suppresses osteoclast differentiation by inhibiting autophagy and Ca2+/calcineurin signaling. Int Immunopharmacol 2022; 25: 160.
34. Chen Z, Bozec A, Ramming A, Schett G. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol 2019; 15: 9-17.
35. Udalova IA, Mantovani A, Feldmann M. Macrophage heterogeneity in the context of rheumatoid arthritis. Nat Rev Rheumatol 2016; 12: 472-85.
36. Liu JH, Zhu YX, Tang XC. Anti-inflammatory and analgesic activities of N-deacetyllappaconitine and lappaconitine. Zhong Guo Yao Li Xue Bao 1987; 8: 301-5.
37. Li X, Wang X, Li Z, et al. A metabolomic study of the analgesic effect of lappaconitine hydrobromide (LAH) on inflammatory pain. Metabolites 2022; 12: 923.
38. Ren W, Rubini P, Tang Y, Engel T, Illes P. Inherent P2X7 receptors regulate macrophage functions during inflammatory diseases. Int J Mol Sci 2021; 23: 232.
39. Qin J, Zhang X, Tan B, et al. Blocking P2X7-mediated macrophage polarization overcomes treatment resistance in lung cancer. Cancer Immunol Res 2020; 8: 1426-39.
40. Wu P, Zhou G, Wu X, Lyu R, Yao J, Wen Q. P2X7 receptor induces microglia polarization to the M1 phenotype in cancer-induced bone pain rat models. Mol Pain 2022; 18: 1-11.
41. Aeschlimann D, Kn?uper V. P2X7 receptor-mediated TG2 externalization: a link to inflammatory arthritis? Amino Acids 2017; 49: 453-60.
42. Baroja-Mazo A, Pelegrín P. Modulating P2X7 receptor signaling during rheumatoid arthritis: new therapeutic approaches for bisphosphonates. J Osteoporos 2012; 3: 408242.
43. Bevaart L, Vervoordeldonk MJ, Tak PP. Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? Arthritis Rheum 2010; 62: 2192-205.
44. Wiley JS, Sluyter R, Gu BJ, Stokes L, Fuller SJ. The human P2X7 receptor and its role in innate immunity. Tissue Antigens 2011; 78: 321-32.
45. Portales-Cervantes L, Ni?o-Moreno P, Doníz-Padilla L, et al. Expression and function of the P2X(7) purinergic receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. Hum Immunol 2010; 71: 818-25.
46. Surprenant A, North RA. Signaling at purinergic P2X receptors. Annu Rev Physiol 2009; 71: 333-59.
47. Shen HH, Yang YX, Meng X, et al. NLRP3: a promising therapeutic target for autoimmune diseases. Autoimmun Rev 2018; 17: 694-702.
48. Di Virgilio F. Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci 2007; 28: 465-72.
49. Omenetti S, Pizarro TT. The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome. Front Immunol 2015; 6: 639.
50. Fasching P, Stradner M, Graninger W, Dejaco C, Fessler J. Therapeutic potential of targeting the Th17/Treg axis in autoimmune disorders. Molecules 2017; 22: 134.
51. Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev 2011; 22: 189-95.
52. Miossec P. The role of interleukin 1 in the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 1987; 5: 305-8.
53. Lopez-Castejon G, Theaker J, Pelegrin P, Clifton AD, Braddock M, Surprenant A. P2X(7) receptor-mediated release of cathepsins from macrophages is a cytokine-independent mechanism potentially involved in joint diseases. J Immunol 2010; 185: 2611-9.
54. Wang D, Br?mme D. Drug delivery strategies for cathepsin inhibitors in joint diseases. Expert Opin Drug Deliv 2005; 2: 1015-28.
55. Adamczyk M, Griffiths R, Dewitt S, Kn?uper V, Aeschlimann D. P2X7 receptor activation regulates rapid unconventional export of transglutaminase-2. J Cell Sci. 2015; 128: 4615-28.
56. Mousseau M, Burma NE, Lee KY, et al. Microglial pannexin-1 channel activation is a spinal determinant of joint pain. Sci Adv 2018; 4: eaas9846.
57. Cutolo M, Campitiello R, Gotelli E, Soldano S. The role of M1/M2 macrophage polarization in rheumatoid arthritis synovitis. Front Immunol 2022; 13: 867260.
58. Fukui S, Iwamoto N, Takatani A, et al. M1 and M2 monocytes in rheumatoid arthritis: a contribution of imbalance of M1/M2 monocytes to osteoclastogenesis. Front Immunol 2018; 8: 1958.
59. Ambarus CA, Noordenbos T, de Hair MJ, Tak PP, Baeten DL. Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitis. Arthritis Res Ther 2012; 14: R74.
60. Wang Y, Han CC, Cui D, Li Y, Ma Y, Wei W. Is macrophage polarization important in rheumatoid arthritis? Int Immunopharmacol 2017; 50: 345-52.
61. MacKay K, Milicic A, Lee D, et al. Rheumatoid arthritis susceptibility and interleukin 10: a study of two ethnically diverse populations. Rheumatology (Oxford) 2003; 42: 149-53.
62. Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M. The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 2004; 15: 61-76.
Options
Outlines

/

〈 〉